Inhibition of human immunodeficiency virus type 1 multiplication by antisense and sense RNA expression. 1991

S Joshi, and A Van Brunschot, and S Asad, and I van der Elst, and S E Read, and A Bernstein
Department of Microbiology, University of Toronto, Ontario, Canada.

Human immunodeficiency virus type 1 (HIV-1) primarily infects CD4+ lymphocytes and macrophages and causes AIDS in humans. Retroviral vectors allowing neomycin phosphotransferase (npt) gene expression were engineered to express 5' sequences of HIV-1 RNA in the antisense or sense orientation and used to transform the human CD4+ lymphocyte-derived MT4 cell line. Cells expressing antisense or sense RNA to the HIV-1 tat mRNA leader sequence, as part of the 3' untranslated region of the npt mRNA, remained sensitive to HIV-1 infection. In contrast, resistance to HIV-1 infection was observed in cells expressing antisense RNA to the HIV-1 primer-binding site or to the region 5' to the primer-binding site as part of the 3' region of the npt mRNA. Cells expressing the tat mRNA leader sequence in the sense orientation as a precise replacement of the 5' untranslated region of npt mRNA were also resistant to HIV-1. These results indicate that sense and antisense approaches can be used to interfere with HIV-1 multiplication.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010957 Plasmids Extrachromosomal, usually CIRCULAR DNA molecules that are self-replicating and transferable from one organism to another. They are found in a variety of bacterial, archaeal, fungal, algal, and plant species. They are used in GENETIC ENGINEERING as CLONING VECTORS. Episomes,Episome,Plasmid
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002472 Cell Transformation, Viral An inheritable change in cells manifested by changes in cell division and growth and alterations in cell surface properties. It is induced by infection with a transforming virus. Transformation, Viral Cell,Viral Cell Transformation,Cell Transformations, Viral,Transformations, Viral Cell,Viral Cell Transformations
D005814 Genes, Viral The functional hereditary units of VIRUSES. Viral Genes,Gene, Viral,Viral Gene
D005822 Genetic Vectors DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition. Cloning Vectors,Shuttle Vectors,Vectors, Genetic,Cloning Vector,Genetic Vector,Shuttle Vector,Vector, Cloning,Vector, Genetic,Vector, Shuttle,Vectors, Cloning,Vectors, Shuttle
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA

Related Publications

S Joshi, and A Van Brunschot, and S Asad, and I van der Elst, and S E Read, and A Bernstein
January 1993, Advances in experimental medicine and biology,
S Joshi, and A Van Brunschot, and S Asad, and I van der Elst, and S E Read, and A Bernstein
June 2000, Antisense & nucleic acid drug development,
S Joshi, and A Van Brunschot, and S Asad, and I van der Elst, and S E Read, and A Bernstein
June 2002, Human gene therapy,
S Joshi, and A Van Brunschot, and S Asad, and I van der Elst, and S E Read, and A Bernstein
June 1990, Biochemical and biophysical research communications,
S Joshi, and A Van Brunschot, and S Asad, and I van der Elst, and S E Read, and A Bernstein
January 1993, Molekuliarnaia biologiia,
S Joshi, and A Van Brunschot, and S Asad, and I van der Elst, and S E Read, and A Bernstein
January 1991, Journal of virology,
S Joshi, and A Van Brunschot, and S Asad, and I van der Elst, and S E Read, and A Bernstein
October 1995, Leukemia,
S Joshi, and A Van Brunschot, and S Asad, and I van der Elst, and S E Read, and A Bernstein
December 1994, Human gene therapy,
S Joshi, and A Van Brunschot, and S Asad, and I van der Elst, and S E Read, and A Bernstein
January 1992, Archives of virology,
S Joshi, and A Van Brunschot, and S Asad, and I van der Elst, and S E Read, and A Bernstein
March 1995, Antiviral research,
Copied contents to your clipboard!